281 related articles for article (PubMed ID: 27229905)
1. An introduction to biomaterial-based strategies for curbing autoimmunity.
Lewis JS; Allen RP
Exp Biol Med (Maywood); 2016 May; 241(10):1107-15. PubMed ID: 27229905
[TBL] [Abstract][Full Text] [Related]
2. Biomaterial Strategies for Immunomodulation.
Hotaling NA; Tang L; Irvine DJ; Babensee JE
Annu Rev Biomed Eng; 2015; 17():317-49. PubMed ID: 26421896
[TBL] [Abstract][Full Text] [Related]
3. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
Froimchuk E; Carey ST; Edwards C; Jewell CM
Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
[TBL] [Abstract][Full Text] [Related]
4. Engineering tolerance using biomaterials to target and control antigen presenting cells.
Tostanoski LH; Gosselin EA; Jewell CM
Discov Med; 2016 May; 21(117):403-10. PubMed ID: 27355336
[TBL] [Abstract][Full Text] [Related]
5. Engineering galectin-glycan interactions for immunotherapy and immunomodulation.
Farhadi SA; Hudalla GA
Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902
[TBL] [Abstract][Full Text] [Related]
6. Improving Vaccine and Immunotherapy Design Using Biomaterials.
Bookstaver ML; Tsai SJ; Bromberg JS; Jewell CM
Trends Immunol; 2018 Feb; 39(2):135-150. PubMed ID: 29249461
[TBL] [Abstract][Full Text] [Related]
7. Engineering antigen-presenting cells for immunotherapy of autoimmunity.
Smith CT; Wang Z; Lewis JS
Adv Drug Deliv Rev; 2024 Jul; 210():115329. PubMed ID: 38729265
[TBL] [Abstract][Full Text] [Related]
8. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells.
Desai N; Hasan U; K J; Mani R; Chauhan M; Basu SM; Giri J
Acta Biomater; 2023 Apr; 161():1-36. PubMed ID: 36907233
[TBL] [Abstract][Full Text] [Related]
9. Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.
Shah SA; Oakes RS; Jewell CM
Adv Drug Deliv Rev; 2024 Jun; 209():115315. PubMed ID: 38670230
[TBL] [Abstract][Full Text] [Related]
10. The use of CD47-modified biomaterials to mitigate the immune response.
Tengood JE; Levy RJ; Stachelek SJ
Exp Biol Med (Maywood); 2016 May; 241(10):1033-41. PubMed ID: 27190273
[TBL] [Abstract][Full Text] [Related]
11. Engineering Immune Tolerance with Biomaterials.
Gammon JM; Jewell CM
Adv Healthc Mater; 2019 Feb; 8(4):e1801419. PubMed ID: 30605264
[TBL] [Abstract][Full Text] [Related]
12. Biomaterial-based approaches to engineering immune tolerance.
Emerson AE; Slaby EM; Hiremath SC; Weaver JD
Biomater Sci; 2020 Dec; 8(24):7014-7032. PubMed ID: 33179649
[TBL] [Abstract][Full Text] [Related]
13. Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity.
Northrup L; Christopher MA; Sullivan BP; Berkland C
Adv Drug Deliv Rev; 2016 Mar; 98():86-98. PubMed ID: 26546466
[TBL] [Abstract][Full Text] [Related]
14. Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes.
Samojlik MM; Stabler CL
Acta Biomater; 2021 Oct; 133():87-101. PubMed ID: 34102338
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Refractory Autoimmune Encephalitis.
Yang J; Liu X
Front Immunol; 2021; 12():790962. PubMed ID: 34975890
[TBL] [Abstract][Full Text] [Related]
16. Antigen-based immunotherapy for autoimmune disease: from animal models to humans?
Tian J; Olcott A; Hanssen L; Zekzer D; Kaufman DL
Immunol Today; 1999 Apr; 20(4):190-5. PubMed ID: 10203718
[TBL] [Abstract][Full Text] [Related]
17. Design of effective immunotherapy for human autoimmunity.
Feldmann M; Steinman L
Nature; 2005 Jun; 435(7042):612-9. PubMed ID: 15931214
[TBL] [Abstract][Full Text] [Related]
18. B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview.
Dolatkhah K; Alizadeh N; Mohajjel-Shoja H; Abdoli Shadbad M; Hajiasgharzadeh K; Aghebati-Maleki L; Baghbanzadeh A; Hosseinkhani N; Karim Ahangar N; Baradaran B
Int J Rheum Dis; 2022 Mar; 25(3):259-271. PubMed ID: 34994525
[TBL] [Abstract][Full Text] [Related]
19. The Emerging Landscape of Immune Cell Therapies.
Weber EW; Maus MV; Mackall CL
Cell; 2020 Apr; 181(1):46-62. PubMed ID: 32243795
[TBL] [Abstract][Full Text] [Related]
20. Immuno-modulatory biomaterials as anti-inflammatory therapeutics.
Lynch RI; Lavelle EC
Biochem Pharmacol; 2022 Mar; 197():114890. PubMed ID: 34990595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
